diabetes treatment

Novo Nordisk investors got a brutal wake-up call this week as shares plummeted over 20% – the company’s worst single-day drop in a decade. The Danish pharmaceutical giant slashed its Wegovy sales forecast amid intensifying competition from Eli Lilly’s superior Zepbound. Here’s what this seismic shift means for the $90 billion obesity drug market. Why […]